[1]
|
Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., et al. (2019) Cancer Treatment and Survivorship Statistics, CA: A Cancer Journal for Clinicians, 69, 363-385. https://doi.org/10.3322/caac.21565
|
[2]
|
Finianos, A., Gupta, K., Clark, B., Simmens, S.J. and Aragon-Ching, J.B. (2017) Characterization of Differences between Prostate Cancer Patients Presenting with De Novo Versus Primary Progressive Metastatic Disease. Clinical Genitourinary Cancer, 16, 85-89. https://doi.org/10.1016/j.clgc.2017.08.006
|
[3]
|
Cooperberg, M.R., Lubeck, D.P., Meng, M.V., Mehta, S.S. and Carroll, P.R. (2004) The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management. Journal of Clinical Oncology, 22, 2141-2149. https://doi.org/10.1200/JCO.2004.10.062
|
[4]
|
Coleman, R.E. (2001) Metastatic Bone Disease: Clinical Features, Pathophysiology and Treatment Strategies. Cancer Treatment Reviews, 27, 165-176. https://doi.org/10.1053/ctrv.2000.0210
|
[5]
|
Belderbos, B.P.S., de Wit, R., Lolkema, M.P.J., Mathijssen, R.H.J., van Soest, R.J. (2019) Novel Treatment Options in the Management of Metastatic Castration Naïve Prostate Cancer; Which Treatment Modality to Choose? Annals of Oncology, 30, 1591-1600. https://doi.org/10.1093/annonc/mdz210
|
[6]
|
Culp, S.H., Schellhammer, P.F. and Williams, M.B. (2014) Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study. European Urology, 65, 1058-1066. https://doi.org/10.1016/j.eururo.2013.11.012
|
[7]
|
Rusthoven, C.G., Jones, B.L., Flaig, T.W., Crawford, E.D., Koshy, M., Sher, D.J., et al. (2016) Improved Survival with Prostate Radiation in Addition to Androgen Deprivation Therapy for Men with Newly Diagnosed Metastatic Prostate Cancer. Journal of Clinical Oncology, 34, 2835-2842. https://doi.org/10.1200/JCO.2016.67.4788
|
[8]
|
Cho, Y., Chang, J.S., Rha, K.H., Hong, S.J., Choi, Y.D., Ham, W.S., et al. (2016) Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasisat Initial Diagnosis? PLoS ONE, 11, e0147191. https://doi.org/10.1371/journal.pone.0147191
|
[9]
|
Papatheofanis, F.J., Williams, E. and Chang, S.D. (2009) Cost-Utility Analysis of the Cyberknife System for Metastatic Spinal Tumors. Neurosurgery, 64, 73-83. https://doi.org/10.1227/01.NEU.0000341205.37067.DE
|
[10]
|
Chow, E., Wu, J.S.Y., Hoskin, P., Coia, L.R., Bentzen, S.M. and Blitzer, P.H. (2002) International Consensus on Palliative Radiotherapy Endpoints for Future Clinical trials in Bone Metastases. Radiotherapy and Oncology, 64, 275-280. https://doi.org/10.1016/S0167-8140(02)00170-6
|
[11]
|
Thureau, S., Vieillard, M.-H., Supiot, S. and Lagrange, J.-L. (2016) Radiothérapie des métastases osseuses. Cancer/Radiothérapie, 20, 227-234. https://doi.org/10.1016/j.canrad.2016.07.027
|
[12]
|
Maher, E.J., Coia, L., Duncan, G. and Lawton, P.A. (1992) Treatment Strategies in Advanced and Metastatic Cancer: Differences in Attitude between the USA, Canada and Europe. International Journal of Radiation Oncology, Biology, Physics, 23, 239-244. https://doi.org/10.1016/0360-3016(92)90568-3
|
[13]
|
Bastié, J.-P., et al. (2019) Points clés de l’annonce pour le cancer dela prostate métastatique. Progrès en Urologie, 29, 908-911. https://doi.org/10.1016/j.purol.2019.10.001
|
[14]
|
Lutz, S., Balboni, T., Jones, J., Lo, S., Petit, J., Rich, S.E., et al. (2017) Palliative Radiation Therapy For Bone Metastases: Update of an ASTRO Evidence-Based Guideline. Practical Radiation Oncology, 7, 4-12. https://doi.org/10.1016/j.prro.2016.08.001
|
[15]
|
International Atomic Energy Agency (2007) Criteria for Palliation of Bone Metastases—Clinical Applications. International Atomic Energy Agency, Vienna, Austria.
|
[16]
|
Nair, B., Wilt, T., MacDonald, R. and Rutks, I. (2002) Early Versus Deferred Androgen Suppression in the Treatment of Advanced Prostatic Cancer. Cochrane Database of Systematic Reviews, 1, Article ID: CD003506. https://doi.org/10.1002/14651858.CD003506
|
[17]
|
van der Linden, Y., Roos, D., Lutz, S. and Fairchild, A. (2009) International Variations in Radiotherapy Fractionation for Bone Metastases: Geographic Borders Define Practice Patterns? Clinical Oncology, 21, 655-658. https://doi.org/10.1016/j.clon.2009.08.004
|
[18]
|
Nakamura, N., Shikama, N., Wada, H., Harada, H., Nozaki, M., Nagakura, H., et al. (2012) Patterns of Practice in Palliative Radiotherapy for Painful Bone Metastases: A Survey in Japan. International Journal of Radiation Oncology, Biology, Physics, 83, 117-120. https://doi.org/10.1016/j.ijrobp.2011.11.075
|
[19]
|
Lievens, Y., Dunscombe, P., Defourny, N., Gasparotto, C., Borras, J.M. and Grau, C. (2015) HERO (Health Economics in Radiation Oncology): A Pan-European Project on Radiotherapy Resources and Needs. Clinical Oncology, 27, 115-124. https://doi.org/10.1016/j.clon.2014.10.010
|
[20]
|
Bradley, N.M.E., Husted, J., Sey, M.S.L., Sinclair, E., Li, K.K., Husain, A.F., et al. (2008) Didthe Pattern of Practice in the Prescription of Palliative Radiotherapy for the Treatment of Uncomplicated Bone Metastases Change between 1999 and 2005 at the Rapid Response Radiotherapy Program? Clinical Oncology, 20, 327-336. https://doi.org/10.1016/j.clon.2008.01.002
|
[21]
|
Rozet, F., et al. (2020) Recommandations francçaises du comité de cancérologie de l’AFU pour le cancer de la prostate: Cancer de prostate métastatique Hormono-Sensible—Actualisation 2020. Progrès en Urologie, 30, 430-438. https://doi.org/10.1016/j.purol.2020.04.017
|
[22]
|
Prostate Cancer Trialists Collaborative Group (2000) Maximum Androgen Blockade in Advanced Prostate Cancer: An Overview of the Randomised Trials. Lancet, 355, 1491-1498. https://doi.org/10.1016/S0140-6736(00)02163-2
|
[23]
|
Kyriakopoulos, C.E., Chen, Y.H., Carducci, M.A., Liu, G., Jarrard, D.F., Hahn, N.M., et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of Clinical Oncology, 36, 1080-1087. https://doi.org/10.1200/JCO.2017.75.3657
|
[24]
|
Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., et al. (2019) Addition of Docetaxel to Hormonal Therapy in Low- and High-Burden Metastatic Hormone Sensitive Prostate Cancer: Long-Term Survival Results from the Stampede Trial. Annals of Oncology, 30, 1992-2003. https://doi.org/10.1093/annonc/mdz248.001
|